NHS England is planning to recruit and ‘army’ of 1,000 social prescribing ‘link workers’ to help alleviate the growing pressure on family doctors.
News
NICE links with EMIG
The National Institute for Health and Care Excellence and the Ethical Medicines Industry Group (EMIG) are working together to increase understanding of the services the Institute offers the life sciences industry.
Global medicine spend forecast to exceed $1.5 trillion by 2023
A new report containing the latest predictions for the global pharmaceutical market has found that global spending on medicines is set to exceed $1.5 trillion by 2023 – marking a 50% increase within seven years.
Horizon and Rutgers Uni form gene editing partnership
Horizon Discovery and Rutgers University signed a partnership deal to commercialise a new gene editing technology.
FDA approves Imbruvica combination for chronic lymphocytic leukaemia
The FDA has approved AbbVie/Johnson & Johnson’s Imbruvica in combination with Roche’s Gazyva in treatment-naïve patients with chronic lymphocytic leukaemia and small lymphocytic lymphoma (CLL/SLL).
Ultomiris successful in Phase III study
Alexion Pharmaceuticals’ Ultomiris has been found to be successful in treating atypical haemolytic uremic syndrome (aHUS) in a Phase III study.
Sensyne to form data science and clinical AI partnerships for chronic disease
Sensyne Health and the University of Oxford’s Big Data Institute have announced plans to establish a world-leading research alliance, using data science and clinical artificial intelligence for the patient-centred management and treatment of chronic disease.
Lords continue to call for clarity on ‘no-deal Brexit’ medicines access
As uncertainty remains on access to medicine in the event of a no-deal Brexit, Lords are continuing to call for clarity on the issue.
Novartis urges government to ‘minimise disruption’ in no-deal Brexit
Novartis has issued a statement expressing concern over the state of medicine supply to the UK, warning that a no-deal Brexit will be “hugely impactful for patients”.
Destiny Pharma to get £1.6M grant for AMR
Destiny Pharma has been awarded a significant new grant funding up to £1.6 million, under the new UK-China antimicrobial resistance (AMR) programme.
NHS “holding its own” despite winter pressures
The NHS’ latest winter report shows increases in emergency department attendances for respiratory conditions, but also an increase on the number of patients admitted, transferred or discharged within the four-hour target.
NHS Employers warning on level of NHS vacancies
The number of unfilled vacanies in the NHS shows the ‘enormous pressure’ the health service is under, NHS Employers has warned.
Rubraca gets EU approval
Clovis Oncology’ Rubraca has been approved by the European Commission for maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Merck gives Vertex exclusive rights to DNA damage inhibitors
Merck has licensed two DNA-dependent protein kinase (DNA-PK) inhibitors back to Vertex Pharmaceuticals.
Circassia pays $32M for rights to AirNOvent
UK group Circassia has announced plans to acquire US and Chinese commercialisation rights to AirNOvent, a novel nitric oxide product, from AIT Therapeutics.
